TuisFTRE • NASDAQ
add
Fortrea Holdings Inc
Vorige sluiting
$19,50
Dagwisseling
$19,18 - $20,14
Jaarwisseling
$16,53 - $41,02
Markkapitalisasie
1,77 mjd USD
Gemiddelde volume
1,32 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Inkomste | 674,90 m | -5,45% |
Bedryfskoste | 157,50 m | 21,53% |
Netto inkomste | -27,90 m | -99,29% |
Netto winsgrens | -4,13 | -110,71% |
Wins per aandeel | 0,23 | -4,17% |
EBITDA | 12,00 m | -72,22% |
Effektiewe belastingkoers | 48,32% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 105,30 m | -4,01% |
Totale bates | 3,66 mjd | -15,13% |
Totale aanspreeklikheid | 2,15 mjd | -18,01% |
Totale ekwiteit | 1,51 mjd | — |
Uitstaande aandele | 89,70 m | — |
Prys om te bespreek | 1,16 | — |
Opbrengs op bates | -0,64% | — |
Opbrengs op kapitaal | -0,85% | — |
Kontantvloei
Netto kontantverandering
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | -27,90 m | -99,29% |
Kontant van bedrywe | -2,40 m | -226,32% |
Kontant van beleggings | -8,10 m | -400,00% |
Kontant van finansiering | -14,00 m | -81,82% |
Netto kontantverandering | -20,90 m | -309,80% |
Beskikbare kontantvloei | -19,35 m | -269,37% |
Meer oor
Fortrea Holdings Inc. is a contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates. Wikipedia
Gestig
Apr. 1996
Webwerf
Werknemers
15 500